Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects.

What It Covers

This review looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

The aim of this article is to briefly review the physiology of growth hormone-releasing hormone (GHRH) and the diagnosis and treatment of GHRH-mediated acromegaly.

Why It Was Studied

Moreover, the role of GHRH and its antagonists in the pathogenesis and treatment of cancer will be reviewed.

Hypothalamic GHRH is secreted into the portal system, binds to specific surface receptors of the somatotroph cell and elicits intracellular signals that modulate pituitary GH synthesis and/or secretion.

What Was Measured

In a retrospective survey of 177 acromegalic patients only a single patient was identified with elevated plasma GHRH levels.

Peripheral GHRH levels are not elevated in patients with hypothalamic GHRH- secreting tumors, supporting the notion that excess eutopic hypothalamic GHRH secretion into the hypophyseal portal system does not appreciably enter the systemic circulation.

The subject headings attached to it are Acromegaly, Diagnosis, Differential, Growth Hormone-Releasing Hormone, Human Growth Hormone, Hypothalamus, Neoplasms, Experimental and Neuroendocrine Tumors.

What This Means in Plain Language

This is a review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

The publication is from 2001 (Annals of oncology : official journal of the European Society for Medical Oncology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.